Kaigene Pharma Deal History & Licensing Activity
Kaigene Pharma is a biotech. Over the past three years, Kaigene Pharma has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Immunology
Kaigene Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Kaigene Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| KG006 | Taisho Pharmaceutical Co., Ltd. | Antibodies | Preclinical | license | Jul 30, 2026 |
| KG006 and KG002 antibody candidates | Celltrion | Other | Unknown | license | Nov 3, 2025 |
Kaigene Pharma Pipeline Focus
Therapeutic areas and modalities where Kaigene Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Kaigene Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Kaigene Pharma Licensing & Deal Activity
Kaigene Pharma is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Kaigene Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Kaigene Pharma include Immunology (4 deals and trials). In terms of modality, Kaigene Pharma has shown particular interest in antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Kaigene Pharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Kaigene Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.